INFLIXIMAB CLEARANCE PRE-THERAPY AND DURING INDUCTION PREDICTS LONG TERM DISEASE CONTROL IN INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Vermeire, Severine
D'Haens, Geert
Laharie, David
Dreesen, Erwin
Rabizadeh, Shervin
Jain, Anjali
Spencer, Elizabeth A.
Panetta, John C.
Dubinsky, Marla
Dervieux, Thierry
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
234
引用
收藏
页码：S45 / S46
页数：2
相关论文
共 50 条
  • [31] Infliximab trough levels after induction therapy are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Hoffman, I.
    Dreesen, E.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S183 - S183
  • [32] Development of anti-infliximab antibodies increases infliximab clearance in chronic inflammatory bowel disease
    Ternant, D.
    Aubourg, A.
    Magdelaine-Beuzelin, C.
    Degenne, D.
    Watier, H.
    Picon, L.
    Paintaud, G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 23 - 23
  • [33] Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
    Loveikyte, Roberta
    Bourgonje, Arno R.
    van der Reijden, Johannes J.
    Bulthuis, Marian L. C.
    Hawinkels, Lukas J. A. C.
    Visschedijk, Marijn C.
    Festen, Eleonora A. M.
    van Dullemen, Hendrik M.
    Weersma, Rinse K.
    van Goor, Harry
    van der Meulen-de Jong, Andrea E.
    Dijkstra, Gerard
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (08) : 1272 - 1284
  • [34] The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease
    Loveikyte, R.
    Bourgonje, A. R.
    van der Reijden, J. J.
    Bulthuis, M. L. C.
    Hawinkels, L. J. A. C.
    van Goor, H.
    van der Meulen-de Jong, A. E.
    Dijkstra, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I244 - I245
  • [35] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [36] Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy
    van Hoeve, Karen
    Tabib, Nasim Sadat Seyed
    Dreesen, Erwin
    Tops, Sophie
    Hoffman, Ilse
    Gils, Ann
    Ferrante, Marc
    Vermeire, Severine
    JOURNAL OF PEDIATRICS, 2022, 240 : 150 - +
  • [37] Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling
    Kimura, Koji
    Yoshida, Atsushi
    Katagiri, Fumihiko
    Takayanagi, Risa
    Yamada, Yasuhiko
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 150
  • [38] Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy
    Foster, EN
    Nguyen, KK
    Bolce, RJ
    Prindiville, TP
    GASTROENTEROLOGY, 2002, 122 (04) : A618 - A618
  • [39] Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease
    Wang, Z.
    Kantasiripitak, W.
    Verstockt, B.
    Joao, S.
    Ferrante, M.
    Declerck, P.
    D'Haens, G.
    Laharie, D.
    Vermeire, S.
    Dreesen, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I131 - I132
  • [40] Infliximab therapy for patients with inflammatory bowel disease: 10 years on
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 623 : S17 - S25
12345